Opinion|Videos|March 3, 2025
The Utility of Newer Topical Therapies for Atopic Dermatitis
Panelists discuss how upcoming topical therapeutics for atopic dermatitis include corticosteroid-sparing treatments like topical calcineurin inhibitors (eg, tacrolimus, pimecrolimus), Janus kinase (JAK) inhibitors (eg, ruxolitinib), and phosphodiesterase-4 inhibitors (eg, crisaborole) for effective symptom management.
Advertisement
Episodes in this series
Video content above in prompted by the following:
- Have the panelists had exposure to the newer therapeutics, such as topical JAK inhibitors?
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
Advertisement
Advertisement
Trending on HCPLive
1
2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics
2
Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG
3
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
4
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
5